Skip Ribbon Commands
Skip to main content
Dr Tao Miriam from National Cancer Centre Singapore

Adj Assoc Prof Tao Miriam


Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Lymphoma

Conditions Treated by this Doctor:

Clinical Appointments

  • Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Adjunct Associate Professor
  • Clinical Senior Lecturer
  • Clinical Teacher


Dr Tao is a Senior Consultant of the Lymphoma Team at National Cancer Centre, Singapore. Her research interests include all areas of care related to Lymphoma with a focus on clinical trials and high dose chemotherapy with autologous peripheral stem cell rescue. She is a member of Singapore Lymphoma Study group and actively involved in prospective trials in both single and multi-centre settings, locally, nationally and internationally.

Dr Tao graduated from London University (Charing Cross Hospital Medical School), UK and undertook her Medical Oncology training in Chinese University of Hong Kong as well as a visiting Fellow at Memorial Sloan Kettering Cancer Centre and Stanford University Medical Centre before joining her current appointment with the Department of Medical Oncology in 1994.

She is also Senior Clinical Lecturer at the Yong Loo Lin School of Medicine for undergraduate education.

She was also Adjunct Associate Professor with Duke-NUS Graduate Medical School Singapore.


  • FHKAM, Hong Kong Academy of Medicine, 1998 
  • FHKCP, Hong Kong College of Physicians, 1994 
  • FAMS, The Academy of Medicine, Singapore, 1995 
  • MRCP, Royal College of Physicians United Kingdom, 1988 
  • MBBS, Charing Cross Hospital Medical School London University, 1984

Professional Appointments and Committee Memberships

  • Chairman of Cluster Electronic Chemotherapy Ordering and Automation Workgroup, 2014 
  • Chair, NCC Blood Transfusion Committee, 2013 - present 
  • SGH DMO Clinical Quality Office, 2013 - present 
  • Fellow, Hong Kong Academy of Medicine, 1998 
  • Member, European Society for Medical Oncology, 1997
  • Medical Director NCC HSCTP, 1996 – present 
  • Director of Apheresis Suite, NCC, 1996 – present 
  • Member, Singapore Society of Oncology, 1996 
  • Fellow, Academy of Medicine Singapore, 1995
  • Fellow, Hong Kong College of Physicians, 1994 
  • Member, American Society of Clinical Oncology, 1994 
  • Member, Hong Kong Medical Association, 1988 
  • Member, Royal College of Physicians (London), 1988


  • American Society of Hematology, Clinical Research Training Institute, 2014 
  • Career Development Award, 2014 
  • American Society of Clinical Oncology Merit Award, 2014 
  • Singhealth Best Registrar Award, 2012 
  • Singhealth Best Registrar Award, 2011 
  • National Healthcare Group (NHG) Doctor Award, 2005
  • NHG/Singhealth Combined Scientific Meeting, 2005 
  • ASEAN (The Association of Southeast Asian Nations) Education Scholarship, 1998

Publications and Research Trials

  • Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres (pattern 1) shows superior survival to patterns 2 and 3: a meta-analysis of 56 cases. Tan LH, Tan SY, Tang T, Lim ST, Tan D, Lim LC, Kam GL, Loh TP, Tao M, Koay ES. Histopathology. 2012 Jan 17. 
  • Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Chiang J, Chan A, Lian T, Tay K, Quek R, Tao M, Lim ST. Asia Pac J Clin Oncol. 2011 Dec;7(4):351-6. 
  • Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. Koo YX, Tan DS, Tan IB, Tai DW, Ha T, Ong WS, Quek R, Tao M, Lim ST. Leuk Lymphoma. 2011 Aug;52(8):1509-16. Epub 2011 Jun 10.

Research Trials

  • A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label study to investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in combination with CHOP or CVP Versus Rituximab IV in Combination with CHOP or CVP in patients With previously untreated follicular lymphoma followed by maintenance treatment with either rituximab SC or Rituximab IV, 2011